Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Resomelagon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Resomelagon overview
Resomelagon is under development for the treatment of systemic inflammatory diseases such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel diseases, peritonitis, systemic lupus erythematosus, multiple sclerosis, and acute respiratory distress syndrome (ARDS) associated with coronavirus COVID-19. The drug candidate is administered orally. It is a phenyl pyrrole aminoguanidine derivative. AP-1189 is an anti-inflammatory compound. It acts as a positive allosteric modulator (PAM) of the melanocortin receptors.
It was under development for the treatment of nephrotic syndrome.
SynAct Pharma overview
SynAct Pharma is a biotechnology company. It carries out in the research and development of medicines for the treatment of inflammatory diseases. The company develops AP1189, a drug candidate for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It also develops TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failures in complicated surgery; and various drug programs to treat auto-immune diseases. SynAct Pharma is headquartered in Lund, Sweden.
For a complete picture of Resomelagon’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
